Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare changes in global left ventricular (LV) function after 3 months of treatment with irbesartan compared with usual care in patients with acute myocardial infarction, a wall motion score >1.3 (EF>0.40) and signs of diastolic dysfunction. The hypothesis is that an angiotensin 2-receptor inhibitor will improve global left ventricular function.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Southern Denmark
• Collaborator: Bristol-Myers Squibb
• Treatments: Angiotensin II; Irbesartan

Criteria

Inclusion Criteria:

• Documented AMI; MPI > 0.55

• Randomized within 7 days of AMI

• Written informed consent

Exclusion Criteria:

• Age < 18 years

• Any contraindications to angiotensin 2-receptor blockade

• In patients with WMSI > 1.3 treatment with ACE-inhibitor or angiotensin 2-receptor blockers

• In patients with WMSI <= 1.3 no initiated or planned treatment with an ACE-inhibitor. Treatment with an ACE-inhibitor must be started within 7 days

• Pregnancy or women of childbearing potential who are not using an effective method of contraception

• Other comorbid conditions that could influence the study

• Currently receiving an experimental study drug